Lurbinectedin trials for Lung cancer

All Lurbinectedin trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Lurbinectedin for Lung cancer

• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
  NCT07459634 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
  NCT07365241 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 63 locations
• Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
  NCT06681220 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
  NCT07153055 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
  NCT06228066 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
  NCT06496048 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
  NCT06497530 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
  NCT05244239 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of Trilaciclib and Lurbinectidin
  NCT05578326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Lurbinectedin for Lung cancer?

12 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.